TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04730154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Description: PNE is a cognitive behavioural intervention, including educating patients that pain is an output product of the brain resulting from input from multiple central and peripheral nervous system processes and leading to threat perception. Transferring that knowledge to patients, allows them to understand, accept and effectively cope with their pain. In order to obtain the targeted behavioural change, motivational interviewing is used as the communication process throughout PNE.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Motivational interviewing is a directive, collaborative, patient-centered communication approach for eliciting and enhancing motivation for behaviour change by helping clients to resolve ambivalence and uncertainty.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biomedically-focused education
Description: The traditional biomedical-focused education programme explains patient's pain experience from a tissue (injured versus healthy tissue) and biomechanical perspective.
Study: NCT06231771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem cells (MSCs)
Description: Dosage · Dosing of IMP is based on ulcer size. The recommended dose is 1 million cells/cm2 of ulcer. Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Dosage · Dosing of placebo is based on ulcer size. the volume will be samed as the experimental groups which is 2 ml per 1cm2 Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
Study: NCT05498415

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive standard of care education information on physical activity, sedentary behavior, and sleep via a mobile app for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive standard of care education information on physical activity, sedentary behavior, and sleep via a mobile app for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Participants will meet with a health coach weekly for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Participants will receive a Fitbit activity monitor to support goal setting and self monitoring of behaviors.
Study: NCT06770907

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) and Breath test
Description: MRI scans and breath test samples collected after drink test with sucrose

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) and Breath test
Description: MRI scans and breath test samples collected after drink test with sucrose
Study: NCT06326983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine (0.1mg/kg given intravenously at induction of anesthesia)
Study: NCT06460571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Cardiac rehabilitation with Delorme technique
Description: Aerobic training will be provided three alternate days a week at 60-70% of maximum heart rate for eight weeks. Resistance training for 3 sets and 10 repetitions (10 lifts with 50%of 10RM, then 75% of 10RM and will progress to 100% of 10RM) will involve seven exercises (abdominal curl ups, bicep curls, triceps extension, back extension, leg curls, side leg raises and knee extensions).
Study: NCT05667805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Concentrate
Description: Liberal use (standard treatment)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prothrombin Complex Concentrate
Description: Liberal use (standard treatment)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restricitve Use
Description: Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
Study: NCT06128980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GDMT
Description: Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi
Study: NCT06057961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: 8 meetings in 1 year
Study: NCT06460571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard cardiac rehabilitation
Description: The control group (Group B) will undergo standard cardiac rehabilitation (outpatient cardiac rehabilitation) which include walking, cycling and strength training which will have 5-10 minutes warm-up followed by training for 30-45 minutes, concluding with cool-down without the Delorme technique. The control group will not perform any specific training but will be given a diet chart to follow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard cardiac rehabilitation
Description: The control group (Group B) will undergo standard cardiac rehabilitation (outpatient cardiac rehabilitation) which include walking, cycling and strength training which will have 5-10 minutes warm-up followed by training for 30-45 minutes, concluding with cool-down without the Delorme technique. The control group will not perform any specific training but will be given a diet chart to follow
Study: NCT05928975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MT+ PNE with MI
Description: The manual therapy treatment approach entailed the management of symptoms based on the clinical judgment of the attending physiotherapist. The physiotherapist selectively employed techniques such as spinal mobilization/manipulation, soft tissue massage, supervised exercises and muscle and neural mobilization, while excluding the utilization of electrophysical modalities. The participants will receive 10 Manual Therapy sessions of 30 minutes within a period of 4 weeks.~The pain neuroscience education program is based on previous clinical studies and available educational materials and is enhanced by motivational interviewing techniques. The program consisted of 4 individualized educational sessions, each lasting 30 minutes. All key aspects of pain neurophysiology were explained and discussed. At the end of the first session, participants will be provided with informational handouts to support the educational process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MT
Description: Participants in this group will be given the same MT program as MT + PNE with MI group without the application of PNE.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The participants in the control group will be provided with written instructions for performing general exercises at home. These exercises will consist of gentle stretching exercises specifically targeting the low back muscles, as well as relief positions and breathing relaxation exercises.
Study: NCT05764486

Intervention type: DEVICE
Group type: OTHER
Intervention: Hitachi's Heavy Ion Beam Therapy System HyBEAT
Description: treating patients with solid tumor
Study: NCT05835869

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography and pattern electroretinogram
Description: Optical coherence tomography angiography is an infrared eye scan that analyzes retinal vascularization and anatomy
Study: NCT05647161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAX602
Description: Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Control Group
Study: NCT04680611

Intervention type: OTHER
Intervention: no study intervention. Patients receive standard clinical care
Description: no intervention. observational study

Intervention type: OTHER
Intervention: no study intervention. Patients receive standard clinical care
Description: no intervention. observational study

Intervention type: OTHER
Intervention: no study intervention. Patients receive standard clinical care
Description: no intervention. observational study
Study: NCT05519735

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multimodality Imaging
Description: Patients receive CXCR4-targeted PET/CT, CMR and Echo
Study: NCT05753956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH002 administered via i.v. bolus injection(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH002 administered via i.v. bolus injection(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH002 administered via i.v. bolus injection(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH002 administered via i.v. bolus injection(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH002 administered via i.v. bolus injection(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH002 administered via i.v. bolus injection(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH002 administered via i.v. bolus injection(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH002 administered via i.v. bolus injection(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH002 placebo administered via i.v. bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH002 placebo administered via i.v. bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH002 placebo administered via i.v. bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH002 placebo administered via i.v. bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH002 placebo administered via i.v. bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH002 placebo administered via i.v. bolus injection
Study: NCT05350696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae plane block (plain pubivicaine)
Description: The erector spinae block is achieved by injecting the local anesthetic solution (with possible adjuvants) between the erector spinae muscles (iliocostalis, longissimus, spinalis/ from lateral to medial) and the transverse process .~The technique is performed under ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine group
Description: patients will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
Study: NCT05768022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cura Kensio-tapping
Description: Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taping
Study: NCT05998889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Education, Graded Pain Exposure Exercises and Graded Motor Imagery. One supervision a week/9 weeks + exercises at home + encourage returning relevant activities despite pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Graded Motor Imagery following the GRaMI protocol, One supervision a week/9 weeks + exercises at home, activities encourage but pain contingency.
Study: NCT05753956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH002 placebo administered via i.v. bolus injection
Study: NCT06127641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care plus pulmonary rehabilitation
Description: A 12-week rehabilitation program, 3X/week. Each outpatient session will last 2 hours including: guidance on the care of inhalation techniques and/or oxygen therapy, when prescribed; aerobic training on a cycle ergometer supervised by a physiotherapist (30 min each: 5 min warm-up, 20 min training and 5 min cool-down) at constant load calculated with Hill's equation (HILL et al., 2008). Optional components of RP will include: inspiratory muscle conditioning using a threshold-loading device, inspiratory muscle training with powerbreathe, breathing exercises, airway clearance, psychological support, relaxation and nutritional counseling. Patients will participate in two group educational sessions, managed by a respiratory physiotherapist, on lifestyle, physical activity and maintenance programs (VISCA et al., 2019; FUGAZZARO et al., 2017; TENCONI et al., 2021).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will receive standard care (SC): a therapeutic education session upon admission, as well as pulmonary rehabilitation (PR) taught by a physical therapist. This therapeutic educational session will involve counseling and self-care management, emphasizing breathing exercises and sputum clearance and self-care techniques. It will consist of smoking cessation education (if this is the case, as tobacco is associated with TB), respiratory retraining (pursed lip breathing, diaphragmatic breathing and segmental breathing) and secretion removal training (coughing exercise, huffing , assisted cough and postural drainage).
Study: NCT04773405

Intervention type: DRUG
Group type: OTHER
Intervention: a 1: 1 mixture of 2% lidocaine with 5ug/ml epinephrine and 0.5% levobupivacaine
Description: This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELAV90) of cases of the aforementioned local anaesthetic (LA) mixture, in order to produce the surgical anaesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries. Based on the principal investigator's clinical experience, the initial volume of 21ml will be used. Depending on the success or failure of the SeTB, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 3ml (1ml for each trunk of brachial plexus located above the clavicle). The upper dose limit of the study to minimize the potential for local anaesthetic systemic toxicity will be 30ml and the lower dose limit will be 12ml, which will be of no clinical importance.
Study: NCT06175897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.~Device: STN-DBS devices DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non-Deep Brain Stimulation
Description: Patients with PD were given their original drug dose and did not receive DBS.
Study: NCT05549115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin-sensitive(first-line)
Description: esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin-resistant(first-line)
Description: esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empirical therapy group first-line
Description: esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin-sensitive(rescue treatment)
Description: esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin-resistant(rescue treatment)
Description: esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empirical therapy group rescue treatment
Description: esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
Study: NCT06280742

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET-MRI with [18F]-DPA-714
Description: PET-MRI with \[18F\]-DPA-714

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI with [18F]-DPA-714
Description: PET-MRI with \[18F\]-DPA-714
Study: NCT05396716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
Study: NCT06128655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in PFCC-IR
Description: PFCC-IR with the critical care team is standard practice in ICU but it doesn't usually include family members. The intervention for this study is interdisciplinary patient care rounds that include one family member of the patient.
Study: NCT06500806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scroth and brace
Description: Participants in this group will wear a brace and follow a 12-month Schroth exercise program three times a week. Sessions will be supervised by a physiotherapist and last 60 minutes, using equipment like foam blocks, exercise balls, and rods. Exercise intensity will gradually increase based on progress. The individualized Schroth exercises will aim to correct spinal deformity and include elongation, rotational correction, stretches, strengthening, and breathing exercises. These exercises will help patients maintain proper posture in daily activities and will be adapted to each participant's abilities, with varying difficulty and positions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brace
Description: Participants in this group will follow only the brace treatment
Study: NCT04711200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived stromal cells intravenously injected
Description: 2×10\^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).
Study: NCT04759300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC VS
Description: patients undergoing tracheal intubation using the C-MAC VS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: C-MAC VL D -blade
Description: patients undergoing intubation using the C-MAC VL D-blade.
Study: NCT05167019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CODE intervention
Description: The CODE intervention consists of 1) One interactive session of 2 to 3 hrs focusing on the concepts of medical-ethical decision-making, the psychological challenge of dealing with ethically sensitive medical topics, and empowering leadership. 2) Observation and debrief of the interdisciplinary meeting to enhance self-reflection on empowering leadership and managing group dynamics. 3) Individual coaching on the spot in self-reflective and empowering leadership and in managing groups dynamics with regard to ethical decision-making about patients who are perceived to receive excessive treatment during the intervention period, and in absence of such patients, every item with regard to ethical decision-making that is important for the coachee. 4) During the intervention coaches and doctors in charge will be informed of the presence of a patient potentially receiving excessive treatment in their ward by an electronic alert.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control group will receive usual care in which the quality of the ethical decision-making is determined by the clinical team according to their usual practice. Except from a treatment-limitation-decisions guideline which focuses on the legal and deontological framework, no other guideline with regard to ethical decision-making has been implemented at the Ghent University Hospital. In one ward (geriatrics), there is a ongoing project in which a clinical nurse specialist stimulates and performes advance care planning conversations with patient and/or relatives at request of the team and who organizes debriefings when needed based on the ethical concerns of the nurses.
Study: NCT04941144

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: COVID-19 Vaccine Intramuscular Injection
Study: NCT04840472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111I-n panitumumab
Description: Imaging Agent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography/computed tomography (SPECT/CT) scans
Description: Day 1 to 5 (Day of Surgery inclusive)